[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-515639-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-515639-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","fsrh-guideline-progestogen-only-pills-august-2022","FSRH Guideline - Progestogen-only Pills - August 2022","","FSRH guideline on progestogen-only pills (POPs) provides clinical recommendations for safe and effective use in sexual and reproductive healthcare. The document states its publication and amendment history, including August 2022 release and later revisions, and specifies how updates are signposted across the FSRH website and BMJ Sexual & Reproductive Health. It includes an evidence-grading framework, lists tables covering key topics, and defines commonly used abbreviations to support consistent interpretation of recommendations.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/fsrh-guideline-progestogen-only-pills-august-2022/515639/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/fsrh-guideline-progestogen-only-pills-august-2022/515639.png","ImageObject",300,407,{"name":42,"@type":43},"Patrick","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-09","2026-10-06",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"When was the progestogen-only pills guideline first published and when was it updated?","Question",{"text":63,"@type":64},"It was first published in March 2015 and the main referenced publication is August 2022, with amendments listed including revisions in October 2022, November 2022, July 2023, and April 2026.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How are updates to the guideline communicated across platforms?",{"text":68,"@type":64},"If a guideline is updated, FSRH replaces the version on its website and the BMJ Sexual & Reproductive Health journal clearly signposts newer versions so older versions are identifiable.",{"name":70,"@type":61,"acceptedAnswer":71},"What grading system is used to classify evidence in the guideline?",{"text":72,"@type":64},"The guideline includes a grading of recommendations based on evidence levels (A, B, C, D) using study quality and applicability, plus Good Practice Points grounded in guideline development group clinical experience.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},515639,1791624537,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":4},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","FSRH Guideline  \nProgestogen-only Pills  \nAugust 2022 (Amended April 2026) FSRH  \nFaculty of Sexual & Reproductive Healthcare (FSRH) provided funding to the Clinical Effectiveness Unit (of the FSRH) to assist them in the production of this guideline,  \nProgestogen-only Pills (August 2022) .  \nPublished by the Faculty of Sexual & Reproductive Healthcare.  \nRegistered in England No. 2804213 and Registered Charity No. 1019969  \nProgestogen-only Pills first published in March 2015.  \nCopyright © Faculty of Sexual & Reproductive Healthcare August 2022.  \nPermission is granted to reproduce or transmit this document for non-commercial personal and non-commercial education use only. Commercial use of any kind, including copying, hiring and lending,  \nis prohibited.  \nAny reproduction of the whole of this document must reproduce this copyright notice in its entirety.  \nAny reproduction of a part of this document must include a statement that it is reproduced under licence from FSRH and the notice Copyright © Faculty of Sexual & Reproductive Healthcare  \nAugust 2022  \nPublished in the UK.  \nNICE has accredited the process used by the Faculty of Sexual & Reproductive Healthcare to produce this guideline. More information on accreditation can be viewed [at www.nice.org.uk/accreditation](at www.nice.org.uk/accreditation).  \nInformation box  \n\n| Title | Progestogen-only Pills August 2022 (Amended April 2026) |\n| --- | --- |\n| Author/publisher | Faculty of Sexual & Reproductive Healthcare |\n| Publication date | August 2022 |\n| Superseded document | Progestogen-only Pills August 2022 (Amended July 2023) |\n| Review date | August 2027 |\n| Available online | [www.cosrh.org/Public/Documents/ceu-guideline-progestogen-only-pills](www.cosrh.org/Public/Documents/ceu-guideline-progestogen-only-pills) |\n\nFrom January 2019 the FSRH has published its electronic clinical guidelines on both its own website ([www.fsrh.org.uk](www.fsrh.org.uk)) and as an electronic supplement to the BMJ Sexual & Reproductive Health (BMJ SRH) journal. The guidelines have the same content. If a guideline is updated, the FSRH replace the version on its website and the BMJ Sexual & Reproductive Health (BMJ SRH) journal will ensure old versions of guidelines will clearly signpost the newer version.  \nTo cite this guideline: FSRH Guideline (August 2022) Progestogen-only Pills. BMJ Sexual & Reproductive Health 2022; 48:Suppl 1. [http://dx.doi.org/10.1136/bmjsrh-2022-PoP](http://dx.doi.org/10.1136/bmjsrh-2022-PoP)  \nDetails of changes to original guidance document  \nSubsequent to the publication of this guideline in August 2022 the following amendments has been made.  \n\n| Date | Revision |\n| --- | --- |\n| 03 October 2022 | Section 10.2 Specific considerations for DRSP POP (page 14)\u003Cbr>First paragraph text has been revised. |\n| 14 November 2022 | Tables 7,9 and 10 – addition of the word ‘active’ in places where it is noted:“Restart/continue DRSP POP until 7 consecutive active pills taken after HFI” |\n| 10 July 2023 | Table 7 updated to reflect extension of 52mg LNG-IUS license from 5 to 6 years\u003Cbr>Section 11.3 Risk of breast cancer updated to reflect newly published evidence |\n| 30 April 2026 | Updated based on UKMEC 2025 |\n\nAbbreviations used   \nAUC  \nBMI  \nCEC  \nCEU  \nCHC  \nCI  \nCOCCu-IUD CVD  \nDMPA  \nDRSP  \nDSG  \nEC  \nEE  \nFSRH  \nGDG  \nHCP  \nHFI  \nHMB  \nHR  \nLARC  \nLNG LNG-IUS  \nMI  \nNET  \nOR  \nPI  \nPOC  \nPOP  \nRCT  \nRP  \nRR  \nRYGB  \nSPC  \nSRH  \nSTI  \nU&E  \nUPA  \nUPSI  \nUSS  \nVTE  \nWHO  \narea under the curve body mass index  \nClinical Effectiveness Committee  \nClinical Effectiveness Unit  \ncombined hormonal contraception/contraceptive confidence interval  \ncombined oral contraception/contraceptive copper intrauterine device cardiovascular disease  \ndepot medroxyprogesterone acetate drospirenone  \ndesogestrel  \nemergency contraception ethinylestradiol  \nFaculty of Sexual & Reproductive Healthcare  \nguideline development group healthcare practitioner hormone-free interval heavy mens","cbCaibKCfbs2T8jp","https://ap.wps.com/l/cbCaibKCfbs2T8jp","pdf",1406001,96,"English","# Information box\n## Title, author/publisher, publication date, superseded and review dates\n# Details of changes to original guidance document\n## Amendment dates and revisions\n# Abbreviations used\n## Full abbreviation list\n# Grading of recommendations\n## Evidence levels and Good Practice Point\n# List of tables\n## Table 1 to Table 10\n# Recommendations following incorrect progestogen-only pill use\n## Vomiting after the progestogen-only pill is taken\n# Medical conditions that are UKMEC3 or UKMEC4 for use of the","[{\"question\":\"When was the progestogen-only pills guideline first published and when was it updated?\",\"answer\":\"It was first published in March 2015 and the main referenced publication is August 2022, with amendments listed including revisions in October 2022, November 2022, July 2023, and April 2026.\"},{\"question\":\"How are updates to the guideline communicated across platforms?\",\"answer\":\"If a guideline is updated, FSRH replaces the version on its website and the BMJ Sexual \\u0026 Reproductive Health journal clearly signposts newer versions so older versions are identifiable.\"},{\"question\":\"What grading system is used to classify evidence in the guideline?\",\"answer\":\"The guideline includes a grading of recommendations based on evidence levels (A, B, C, D) using study quality and applicability, plus Good Practice Points grounded in guideline development group clinical experience.\"}]","FSRH Guideline - Progestogen-only Pills - August 2022 | PDF",1791320643,242]